Cellectar Reports First Quarter 2019 Financial Results and Provides a Corporate Update

May 6, 2019

FDA Grants Exemption to Import Alert for Cellectar’s CLR 131 in Pediatric and Adolescent Patients

Mar 19, 2019

Cellectar Reports Financial Results for Year Ended December 31, 2018 and Provides a Corporate Update

Feb 26, 2019

Cellectar Reports Positive Top-line Response Rate of 30% from R/R Multiple Myeloma Cohort in Ongoing Phase 2 Study of CLR 131

Feb 25, 2019

Cellectar Biosciences to Present at the Annual BIO CEO & Investor Conference

Feb 5, 2019

Cellectar Biosciences to Present at NobleConXV, Noble Capital Markets’ Fifteenth Annual Investor Conference

Jan 23, 2019

Cellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple Myeloma

Jan 7, 2019

Cellectar Biosciences to Present at the Biotech Showcase

Jan 3, 2019

Cellectar Granted Japanese Patent for CLR 131

Dec 11, 2018

Cellectar Initiates Cohort 6 of Phase 1b Trial Evaluating CLR 131 in Relapsed/Refractory Multiple Myeloma

Dec 4, 2018